股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 華領醫藥 | | | | | | 呈交日期: | 2026年2月5日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02552 | 說明 | 普通股 | | | | | 法定/註冊股份數目 | 面值 | | 法定/註冊股本 | | | --- | --- | --- | --- | --- | --- | | 上月底結存 | 2,000,000,000 | USD | 0.001 USD | | 2,000,000 | | 增加 / 減少 (-) | | | USD | | | | 本月底結存 | 2,000,000,000 | USD | 0. ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年12月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 華領醫藥 | | | 呈交日期: | 2026年1月7日 | | | I. 法定/註冊股本變動 | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02552 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.001 USD | | 2,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD ...

Group 1 - The article discusses various companies including 创新奇智, 北部湾港, and 矽电股份, highlighting their recent developments and market positions [2] - It mentions 中直股份 and 兴福电子 as key players in their respective sectors, indicating their growth potential and strategic initiatives [2] - The performance of 吉贝尔 and 华资实业 is analyzed, focusing on their financial results and market trends [2] Group 2 - 莱特光电 and 华领医药 are noted for their innovative approaches and contributions to technology and healthcare industries [2] - 福莱新材 and 赛力斯 are highlighted for their advancements in materials science and potential impact on the market [2]

Core Viewpoint - The "Annual Outstanding Biopharmaceutical Company" award was presented to Hualing Pharmaceutical-B (02552.HK) during the "Technology Empowerment · Capital Breakthrough" online sharing session held by Gelonghui on December 22 [1] Group 1 - The award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications in the biopharmaceutical field [1] - The evaluation criteria for the award include technological innovation, research and development strength, and the ability to translate results into practical applications [1]

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award was announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies were awarded, including Baillie Tianheng (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, listed in alphabetical order [1] Group 2: Evaluation Criteria - The evaluation for the award was based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were derived through quantitative data analysis and expert review [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

Core Insights - The "Annual Outstanding Biopharmaceutical Enterprises" award recognizes companies with independent core technologies, continuous innovation, and effective transformation of research results into clinical or commercial applications [4] Group 1: Award Announcement - The "Annual Outstanding Biopharmaceutical Enterprises" award will be announced during the "Technology Empowerment, Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1] - Eight companies, including Baillie Gifford (688506.SH), Dongyang Sunshine Pharmaceutical (06887.HK), Dongyao Pharmaceutical-B (01875.HK), and others, have been awarded the title [1] Group 2: Evaluation Criteria - The evaluation for the award is based on a comprehensive assessment of technical innovation, research and development strength, and achievement transformation [4] - The final results were determined through quantitative data analysis and an expert review panel [4] Group 3: Purpose of the Award - Gelonghui aims to create a reference value ranking for listed companies and unicorns in the investment community with the "Golden Gelong Award" [4] - The award covers all listed companies and unicorns on major exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4]

Core Viewpoint - HuaLing Pharmaceutical-B (02552) has seen a stock increase of over 3%, currently at 3.25 HKD, following the announcement of the successful administration of the first patient in a multi-dose escalation (MAD) Phase Ib trial for HMS1005, a second-generation glucose kinase activator [1][2]. Group 1: Clinical Trial Details - The Phase Ib trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in Type 2 diabetes (T2D) subjects in the U.S. [1] - The study will assess pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon, as well as monitor blood glucose fluctuations using continuous glucose monitoring (CGM) [1]. Group 2: Drug Characteristics - HMS1005 is a novel molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow for once-daily dosing, enhancing patient convenience and prolonging the drug's duration in the intestine [1]. - The drug aims to improve the repair capacity of patients with insufficient GLP-1 secretion [1]. Group 3: Future Plans - Following the successful completion of the MAD Ib study, the company plans to seek partners for the global development of HMS1005 [2].

Core Viewpoint - 华领医药-B (02552.HK) experienced a price increase of over 3%, reaching HKD 3.25 with a trading volume of HKD 3.303 million [2] Group 1 - The stock rose by 3.17% as of the time of reporting [2] - The current trading price is HKD 3.25 [2] - The total trading volume recorded is HKD 3.303 million [2]

Core Viewpoint - HuaLing Pharmaceutical-B (02552) has seen a stock increase of over 3% following the successful administration of the first patient in the MAD Ib trial of its second-generation glucose kinase activator (GKA), HMS1005, in the United States [1][2] Group 1: Trial Details - The MAD Ib trial is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMS1005 in Type 2 diabetes (T2D) patients in the U.S. [1] - The study will assess pharmacodynamic markers such as blood glucose, insulin, C-peptide, GLP-1, and glucagon, as well as monitor blood glucose fluctuations using continuous glucose monitoring (CGM) [1] Group 2: Drug Characteristics - HMS1005 is a new molecular entity with improved physicochemical properties, designed as a sustained-release formulation to allow once-daily dosing, enhancing patient convenience and increasing the duration of the drug's action in the intestine [2] - The company has previously completed and published results from a single-dose escalation study of HMS1005, confirming its feasibility for once-daily oral treatment in T2D and obesity patients [2] Group 3: Future Plans - Following the successful completion of the MAD Ib trial, the company plans to seek partners for the global development of HMS1005 [2]

Group 1 - The core viewpoint of the news is that HuaLing Pharmaceutical has successfully completed the first dosing of its second-generation glucose kinase activator (GKA) HMS1005 in a Phase Ib multiple ascending dose (MAD) trial in the United States, marking a significant step in expanding its presence in the overseas diabetes market [1][2] - HMS1005 is designed as a novel molecular entity with improved physicochemical properties, featuring a sustained-release formulation that allows for once-daily dosing, enhancing patient convenience and potentially improving adherence to treatment [1] - The successful completion of the Phase Ib clinical trial will lead the company to seek partnerships for the global market development of HMS1005, further solidifying its leading position in the global GKA sector [1] Group 2 - The CEO of HuaLing Pharmaceutical, Dr. Chen Li, emphasized that the initiation of the Phase Ib clinical trial in the U.S. is a critical step in leading the innovation of diabetes drug development and overseas market expansion [2] - The company aims to validate the safety and tolerability of the second-generation GKA through robust trial design and strong R&D execution, laying a solid foundation for future clinical development [2] - HuaLing Pharmaceutical is committed to exploring better treatment options while deepening its existing product market, with plans to continue advancing more innovative drugs and global outreach to provide new treatment hopes for patients with type 2 diabetes [2]